Huayuan Securities gives Baio Saitu a "Buy" rating, as model organism performance accelerates realization, and AI empowers antibody development.

Every Daily AI News Express: Huayuan Securities released a research report on April 3 stating that it gives BaiOgen (688796.SH, latest price: 112.3 yuan) a “Buy” rating. The rating rationale mainly includes: 1) BaiOgen is an international biotechnology company driven by innovative technology in drug R&D, committed to providing high-quality products and services for the new drug R&D sector; 2) The “Thousands of Mice and Ten Thousand Antibodies” program has been comprehensively upgraded, with an AI and automation platform empowering early-stage R&D; 3) The preclinical products and services business maintains high growth, and innovative animal models build core competitive advantages. Risk warning: the risk that the company’s candidate drug screening cannot meet customer needs; the risk that animal models cannot meet customer needs; the risk of technological upgrade and iteration; the risk of changes in industry policies; the risk of overseas operations and exchange rate fluctuations.

Every Daily Headlines (nbdtoutiao) — Raising one pig loses 400 yuan! Hog prices have fallen for 8 straight weeks; in Hainan, it’s only 7.9 yuan per kilogram. The government has started reserve purchases, and experts predict that the turning point of the pork cycle will occur as early as the end of the second quarter this year

(Reporter: Zeng Jianhui)

Disclaimer: The content and data in this article are for reference only and do not constitute investment advice. Please verify before using. If you act on this, you assume the risks.

Daily Economic News